Skip to content

Study · Randomized controlled trial · n = 42 · 1990

3 results

Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.

Costantini S, Anserini P, Valenzano M, Remorgida V, Venturini PL, De Cecco L

European journal of obstetrics, gynecology, and reproductive biology1 Oct 1990Cited by 17 (Europe PMC)

PMID2142921 (opens in a new tab)DOI10.1016/0028-2243(90)90096-j (opens in a new tab)PepBankPUB-02142921
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In uterine fibroid patients, fibroid reduction did not differ significantly between goserelin and buserelin.

    In plain wordsIn uterine fibroid patients, fibroid reduction did not differ significantly between goserelin and buserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeFibroid reduction
    Study

    n = 42

    Comparator
    Buserelin
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There were no significative differences in fibroid reduction between the two treatment groups.
    1 context sentence
    Summary · context
    42 patients were randomly assigned to receive either intranasal buserelin, preceded by a short period of subcutaneous injections (500 micrograms thrice daily for 10 days) or subcutaneous goserelin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with uterine fibroids, fibroid volume fell by more than 30% after 6 months in 18 goserelin patients and 16 buserelin patients, with no significant difference between the groups.

    In plain wordsAfter 6 months, fibroids shrank over 30% in 18 goserelin patients and 16 buserelin patients, with no significant difference between treatments.

    Peptide
    Goserelin
    Outcome
    No significant changeFibroid reduction exceeding 30%
    Study

    n = 42

    Comparator
    Buserelin
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Patients with fibroid volume reduction >30%
    18 patients
    goserelin group, 6 months
    Patients with fibroid volume reduction >30%
    16 patients
    buserelin group (comparator), 6 months

    Source sentences

    Summary
    There were no significative differences in fibroid reduction between the two treatment groups.
    Summary
    After 6 months of treatment, a fibroid reduction of more than 30% of the initial volume was observed in 16 patients in the buserelin group and in 18 patients in the goserelin group.
    1 context sentence
    Summary · context
    42 patients were randomly assigned to receive either intranasal buserelin, preceded by a short period of subcutaneous injections (500 micrograms thrice daily for 10 days) or subcutaneous goserelin.
  3. 03HumanNon-randomized trialEfficacy outcome

    In uterine fibroid patients, fibroid regrowth occurred in all patients during follow-up after goserelin or buserelin treatment.

    In plain wordsIn uterine fibroid patients, fibroids regrew in all patients during follow-up after goserelin or buserelin treatment.

    Peptide
    Goserelin
    Outcome
    IncreaseFibroid regrowth
    Study

    n = 42

    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The fibroid regrowth observed in all patients during the follow-up period severely limits the usefulness of this medical approach to selected clinical cases.
    1 context sentence
    Summary · context
    42 patients were randomly assigned to receive either intranasal buserelin, preceded by a short period of subcutaneous injections (500 micrograms thrice daily for 10 days) or subcutaneous goserelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.